| abstract |
The present invention is a cancer selected from the group consisting of carcinoma, sarcoma, melanoma, myeloma, hematologic tumor, lymphoma, childhood cancer and leukemia, amyloidosis, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic sclerosis (sclerosis), Mammals of humans or non-humans, such as diseases caused by fungi and autoimmune diseases selected from the group consisting of mixed connective tissue diseases, Sjogren's syndrome, ankylosing spondylitis, autoimmune vasculitis, Behcet's syndrome, psoriasis, autoimmune arthritis, sarcoidosis and diabetes The use of a compound of formula (I) for the treatment of diseases characterized by abnormal cell proliferation in the body of animals by inhibiting polo-like kinase (PLK) as a mitotic regulator.n n n Formula In n n n n n n n Dihydrophteridinone, PLK, Mitosis Modulator |